BioMarin Pharma (BMRN) Posts Q4 Loss of $0.03/Share
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $64.63 -2.86%
Revenue Growth %: +32.7%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +32.7%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 GAAP EPS of ($0.03), which may not compare to the analyst estimate of ($0.24). Revenue for the quarter came in at $353.2 million versus the consensus estimate of $377.35 million.
GUIDANCE:
BioMarin Pharma sees FY2019 revenue of $1.68-1.75 billion, versus the consensus of $1.73 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- BMO Capital Starts American Eagle Outfitters (AEO) at Market Perform
- Barnes & Noble Education (BNED) Tops Q1 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
